Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313374671> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4313374671 endingPage "91.9" @default.
- W4313374671 startingPage "91.9" @default.
- W4313374671 abstract "Abstract B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematopoietic neoplasm characterized by recurrent genetic lesions resulting in malignant transformation. Despite an arrest in B cell maturation, human B-ALL blasts retain the capacity for reprogramming to the myeloid lineage. To test the therapeutic implications of reprogramming, we generated murine models of B-ALL capable of myeloid lineage reprogramming via ectopic expression of CEBPα and PU.1. Once reprogrammed, B-ALL cells acquired an APC phenotype and stimulated antigen-specific T cells. In vivo B-ALL reprogramming in immunodeficient mice led to a modest survival benefit, however, reprogramming in immunocompetent mice led to tumor eradication and protection from subsequent re-challenge, demonstrating successful generation of durable, systemic, and curative immunity. This therapeutic benefit is dependent on the presence of both CD4+ and CD8+ T cells, and characterized by an increased frequency of bone marrow-infiltrating T cells and oligoclonal T cell expansion. Moreover, local myeloid reprogramming of a primary tumor drove systemic immune activation and eradication of distant, non-reprogrammed lesions. Our data suggests that B-ALL cells reprogrammed to the myeloid lineage are potent APCs capable of presenting tumor-associated antigens, and in vivo reprogramming elicits robust, durable, tumor-eradicating, and systemic T cell-mediated immunity. Recent efforts have further identified sarcoma and carcinoma models amenable to myeloid-lineage reprogramming. Thus, reprogramming of malignant cells into APCs represents a novel immunotherapeutic strategy with potential clinical utility in the treatment of a broad array of human malignancies." @default.
- W4313374671 created "2023-01-06" @default.
- W4313374671 creator A5006372534 @default.
- W4313374671 creator A5011396363 @default.
- W4313374671 creator A5038619702 @default.
- W4313374671 creator A5039059962 @default.
- W4313374671 creator A5051785171 @default.
- W4313374671 creator A5057316768 @default.
- W4313374671 creator A5062964305 @default.
- W4313374671 creator A5064845921 @default.
- W4313374671 creator A5084923779 @default.
- W4313374671 date "2020-05-01" @default.
- W4313374671 modified "2023-10-02" @default.
- W4313374671 title "Reprogramming leukemia cells into antigen presenting cells as a novel cancer vaccination immunotherapy" @default.
- W4313374671 doi "https://doi.org/10.4049/jimmunol.204.supp.91.9" @default.
- W4313374671 hasPublicationYear "2020" @default.
- W4313374671 type Work @default.
- W4313374671 citedByCount "0" @default.
- W4313374671 crossrefType "journal-article" @default.
- W4313374671 hasAuthorship W4313374671A5006372534 @default.
- W4313374671 hasAuthorship W4313374671A5011396363 @default.
- W4313374671 hasAuthorship W4313374671A5038619702 @default.
- W4313374671 hasAuthorship W4313374671A5039059962 @default.
- W4313374671 hasAuthorship W4313374671A5051785171 @default.
- W4313374671 hasAuthorship W4313374671A5057316768 @default.
- W4313374671 hasAuthorship W4313374671A5062964305 @default.
- W4313374671 hasAuthorship W4313374671A5064845921 @default.
- W4313374671 hasAuthorship W4313374671A5084923779 @default.
- W4313374671 hasConcept C109159458 @default.
- W4313374671 hasConcept C147483822 @default.
- W4313374671 hasConcept C1491633281 @default.
- W4313374671 hasConcept C203014093 @default.
- W4313374671 hasConcept C2777701055 @default.
- W4313374671 hasConcept C2778461978 @default.
- W4313374671 hasConcept C2778729363 @default.
- W4313374671 hasConcept C2779282312 @default.
- W4313374671 hasConcept C2780674031 @default.
- W4313374671 hasConcept C28328180 @default.
- W4313374671 hasConcept C502942594 @default.
- W4313374671 hasConcept C54355233 @default.
- W4313374671 hasConcept C77255625 @default.
- W4313374671 hasConcept C86803240 @default.
- W4313374671 hasConcept C8891405 @default.
- W4313374671 hasConcept C95444343 @default.
- W4313374671 hasConceptScore W4313374671C109159458 @default.
- W4313374671 hasConceptScore W4313374671C147483822 @default.
- W4313374671 hasConceptScore W4313374671C1491633281 @default.
- W4313374671 hasConceptScore W4313374671C203014093 @default.
- W4313374671 hasConceptScore W4313374671C2777701055 @default.
- W4313374671 hasConceptScore W4313374671C2778461978 @default.
- W4313374671 hasConceptScore W4313374671C2778729363 @default.
- W4313374671 hasConceptScore W4313374671C2779282312 @default.
- W4313374671 hasConceptScore W4313374671C2780674031 @default.
- W4313374671 hasConceptScore W4313374671C28328180 @default.
- W4313374671 hasConceptScore W4313374671C502942594 @default.
- W4313374671 hasConceptScore W4313374671C54355233 @default.
- W4313374671 hasConceptScore W4313374671C77255625 @default.
- W4313374671 hasConceptScore W4313374671C86803240 @default.
- W4313374671 hasConceptScore W4313374671C8891405 @default.
- W4313374671 hasConceptScore W4313374671C95444343 @default.
- W4313374671 hasIssue "1_Supplement" @default.
- W4313374671 hasLocation W43133746711 @default.
- W4313374671 hasOpenAccess W4313374671 @default.
- W4313374671 hasPrimaryLocation W43133746711 @default.
- W4313374671 hasRelatedWork W2023771859 @default.
- W4313374671 hasRelatedWork W2075542228 @default.
- W4313374671 hasRelatedWork W2115640225 @default.
- W4313374671 hasRelatedWork W2121159001 @default.
- W4313374671 hasRelatedWork W2260322567 @default.
- W4313374671 hasRelatedWork W2904151100 @default.
- W4313374671 hasRelatedWork W2937326325 @default.
- W4313374671 hasRelatedWork W2997253459 @default.
- W4313374671 hasRelatedWork W4210379329 @default.
- W4313374671 hasRelatedWork W4311666177 @default.
- W4313374671 hasVolume "204" @default.
- W4313374671 isParatext "false" @default.
- W4313374671 isRetracted "false" @default.
- W4313374671 workType "article" @default.